Intellia Therapeutics (NTLA) Cash from Operations (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Operations data on file, last reported at 117346000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 21.21% year-over-year to 117346000.0 in Q1 2026; TTM through Mar 2026 was 363152000.0, a 3.71% increase from a year earlier, with the FY2025 full-year figure at 394736000.0, down 13.14% from the prior year.
• Cash from Operations for Q1 2026 stood at 117346000.0, down from 69285000.0 in the prior quarter.
• Over the last five years, Cash from Operations for NTLA reached as high as 58186000.0 in Q2 2024 and fell as low as 148930000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 93431470.59 across 5 years, with a median of 89869000.0 in 2022.
• Across the five-year window, Cash from Operations jumped 35.58% in 2024 and tumbled 71.21% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 89869000.0 in 2022, then fell by 3.54% to 93054000.0 in 2023, then increased by 8.45% to 85195000.0 in 2024, then gained by 18.67% to 69285000.0 in 2025, then sank by 69.37% to 117346000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 117346000.0 in Q1 2026, 69285000.0 in Q4 2025, and 76899000.0 in Q3 2025.